IL-22BP controls the progression of liver metastasis in colorectal cancer.
IL-22BP
cancer therapy
colorectal cancer
metastasis
tumor immunology
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
02
2023
accepted:
16
05
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. We used two different murine Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.
Sections du résumé
Background
UNASSIGNED
The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown.
Methods
UNASSIGNED
We used two different murine
Results
UNASSIGNED
Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine
Conclusions
UNASSIGNED
We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.
Identifiants
pubmed: 37324022
doi: 10.3389/fonc.2023.1170502
pmc: PMC10265988
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1170502Informations de copyright
Copyright © 2023 Giannou, Kempski, Zhang, Lücke, Shiri, Zazara, Belios, Machicote, Seeger, Agalioti, Tintelnot, Sagebiel, Tomczak, Bauditz, Bedke, Kocheise, Mercanoglu, Fard-Aghaie, Giorgakis, Lykoudis, Pikouli, Grass, Wahib, Bardenhagen, Brunswig, Heumann, Ghadban, Duprée, Tachezy, Melling, Arck, Stringa, Gentilini, Gondolesi, Nakano, Thomson, Perez, Li, Mann, Izbicki, Gagliani, Maroulis and Huber.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2016 Oct 21;354(6310):358-362
pubmed: 27846573
J Clin Invest. 2008 Feb;118(2):534-44
pubmed: 18172556
Cancer Metastasis Rev. 2011 Mar;30(1):5-12
pubmed: 21249426
Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38
pubmed: 16537974
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
EMBO Mol Med. 2017 May;9(5):672-686
pubmed: 28341702
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
J Clin Invest. 2015 Dec;125(12):4529-43
pubmed: 26571401
Cancers (Basel). 2021 May 17;13(10):
pubmed: 34067631
Immunity. 2020 Nov 17;53(5):1015-1032.e8
pubmed: 33207209
Nat Commun. 2020 May 25;11(1):2608
pubmed: 32451418
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Nature. 2015 Dec 24;528(7583):560-564
pubmed: 26649819
J Exp Med. 2009 Jul 6;206(7):1465-72
pubmed: 19564350
J Clin Oncol. 2011 Feb 20;29(6):601-3
pubmed: 21245434
Mucosal Immunol. 2014 Jan;7(1):101-13
pubmed: 23653115
Nature. 2019 Feb;566(7743):249-253
pubmed: 30700914
Front Immunol. 2017 Oct 25;8:1373
pubmed: 29118756
J Immunol. 2001 Jun 15;166(12):7096-103
pubmed: 11390454
Nature. 2012 Nov 8;491(7423):259-63
pubmed: 23075849
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9511-6
pubmed: 11481447
Immunity. 2014 May 15;40(5):772-784
pubmed: 24816405
J Vis Exp. 2014 Sep 27;(91):51677
pubmed: 25285458
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
J Exp Med. 2013 May 6;210(5):917-31
pubmed: 23589566
Immunity. 2023 Jan 10;56(1):125-142.e12
pubmed: 36630911
Clin Immunol. 2013 Apr;147(1):38-39
pubmed: 23501837
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Gastroenterology. 2020 Oct;159(4):1417-1430.e3
pubmed: 32585307
Mucosal Immunol. 2016 Mar;9(2):539-49
pubmed: 26329427